

Overview

Useful For

Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of an underlying red blood cell enzymopathy

Identifying variants within genes associated with phenotypic severity, allowing for predictive testing and further genetic counseling

Genetics Test Information

For a list of the genes and exons targeted by this test, see [Targeted Genes Interrogated by NGENZ Next-Generation Sequencing](#).

Special Instructions

- [Informed Consent for Genetic Testing](#)
- [Targeted Genes Interrogated by NGENZ Next-Generation Sequencing](#)
- [Metabolic Hematology Next-Generation Sequencing \(NGS\) Patient Information](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)
- [NGHHA and Subpanel Comparison Gene List](#)

Method Name

Next-Generation Sequencing (NGS)

NY State Available

Yes

Specimen

Specimen Type

Varies

Ordering Guidance

Multiple hematology gene panels are available. For more information, see [NGHHA and Subpanel Comparison Gene List](#).

Additional Testing Requirements

This panel aids in the diagnosis and genetic counseling of individuals with inherited red blood cell enzymopathies, possible carrier states, or compound variants with severity modulating interactions. This panel always should be interpreted in the context of protein functional findings by enzymatic assay and complete blood count and peripheral blood findings. This complete interpretation can be provided by also ordering the EEEV1 / RBC Enzyme Evaluation.

Please fill out the information sheet and indicate that a next-generation sequencing test was ordered. Providing complete blood cell count data and clinical notes will also allow more precise interpretation of results.

Shipping Instructions

Peripheral blood specimens must arrive within 30 days of collection.

Necessary Information

1. [Metabolic Hematology Next-Generation Sequencing \(NGS\) Patient Information](#) is required. Testing may proceed without the patient information, however, the information aids in providing a more thorough interpretation. Ordering providers are strongly encouraged to fill out the form and send with the specimen.
2. If form not provided, include the following information with the test request: clinical diagnosis, pertinent clinical history (ie, complete blood cell count results and relevant clinical notes) and differentials based on clinical or morphologic presentation.

Specimen Required

Submit only 1 of the following specimens:

Specimen Type: Peripheral blood (preferred)

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top or (ACD)

Acceptable: Green top (heparin)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot**
3. Label specimen as blood

Specimen Stability: Refrigerated < or =30 days

Specimen Type: Extracted DNA

Container/Tube: 1.5- to 2-mL tube

Specimen Volume: Entire specimen

Collection Instructions:

1. Indicate volume and concentration of the DNA.
2. Label specimen as extracted DNA and source of specimen.

Specimen Stability: Frozen/Refrigerated/Ambient < or =30 days

Forms

1. [Metabolic Hematology Next-Generation Sequencing \(NGS\) Patient Information](#) is required.
2. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file.

 -[Informed Consent for Genetic Testing](#) (T576)

 -[Informed Consent for Genetic Testing-Spanish](#) (T826)
3. [If not ordering electronically, complete, print, and send a Benign Hematology Test Request](#) (T755) with the specimen.

Reject Due To

Gross hemolysis	Reject
Gross lipemia	OK
Bone marrow biopsies	Reject
Slides	
Paraffin shavings	
Frozen tissues	
Paraffin-embedded tissues	
Paraffin-embedded bone marrow aspirates	

Specimen Minimum Volume

Blood, Bone Marrow: 1 mL

Extracted DNA: 100 mcL at 20 ng/mcL concentration

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Varies (preferred)		

Clinical & Interpretive

Clinical Information

Next-generation sequencing (NGS) is a methodology that can interrogate large regions of genomic DNA in a single assay. The presence and pattern of gene variants can provide critical diagnostic, prognostic, and therapeutic information for managing physicians.

Mature erythrocytes are dependent upon glycolysis for energy production and the hexose monophosphate shunt for oxidation-reduction stability. Hereditary deficiencies in red blood cell (RBC) enzymes within these pathways cause nonspherocytic hemolytic anemia with variable clinical presentations, therapeutic considerations and inheritance patterns.(1-3) Most of these deficiencies cause chronic hemolysis with little to no pathognomonic morphologic changes in the peripheral blood smear making correlation with enzyme activity critical for diagnosis. Some are associated with acute episodic anemia triggered by medications, food, or viral illness. Variable additional symptoms may be present for some deficiency types, including myopathy, neuropathy, and developmental delay. Because a subset of clinically significant RBC enzyme disorders can have indeterminate to normal enzyme activity (masking in the presence of increased reticulocytes), the protein (enzymatic activity) studies are more sensitive when performed as a panel of RBC enzymes, which allows comparison of multiple enzyme activities. This genetic panel can aid in the interpretation of equivocal protein findings and genetically confirm an enzyme deficiency. Additionally, there are genes interrogated on this panel for which an enzyme test is not clinically available for correlation.

Reference Values

An interpretive report will be provided.

Interpretation

Evaluation and categorization of variants is performed using the most recent published American College of Medical Genetics recommendations as a guideline.(4) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Multiple in silico evaluation tools may be used to assist in the interpretation of these results. The accuracy of predictions made by in silico evaluation tools is highly dependent upon the data available for a given gene, and predictions made by these tools may change over time. Results from in silico evaluation tools should be interpreted with caution and professional clinical judgment.

Cautions

Clinical:

Some individuals may have a variant that is not identified by the methods performed. The absence of a variant, therefore, does not eliminate the possibility of hereditary hemolytic anemia or a related disorder. This assay does not distinguish between germline and somatic alterations, particularly with variant allele frequencies significantly lower than 50%. Test results should be interpreted in context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

If there is a family history of hereditary hemolytic anemia or a related disorder, it is often useful to test first-degree family members to help establish the clinical significance of variants of unknown significance.

At this time, it is not standard practice for the laboratory to systematically review likely disease-associated variants or variants of uncertain significance that have been previously detected and reported. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time.

Technical:

Some genetic or genomic alterations, such as large deletion/insertions (delin) events, copy number alterations and gene translocation events are not detected by this assay. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Additionally, rare variants (ie, polymorphisms) may be present that could lead to false negative or positive results. If results do not match clinical findings, consider alternative methods for analyzing these genes, such as Sanger sequencing or large deletion/duplication analysis. If the patient has had an allogenic blood transfusion, these results may be inaccurate due to the presence of donor DNA.

Clinical Reference

1. Orkin SH, Nathan DG, Ginsburg D, et al, eds. Nathan and Oski's Hematology of Infancy and Childhood. 7th ed. Saunders Elsevier; 2009:360-364
2. Iolascon A, Andolfo I, Barcellini W, et al: Recommendations for splenectomy in hereditary hemolytic anemias. *Haematologica*. 2017 May 26. PMID: 28550188. doi: 10.3324/haematol.2016.161166.
3. Koralkova P, van Solinge WW, van Wijk R: Rare hereditary red blood cell enzymopathies associated with hemolytic anemia - pathophysiology, clinical aspects, and laboratory diagnosis. *Int J Lab Hematol*. 2014 Jun;36(3):388-397
4. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015 May;17(5):405-424

Performance**Method Description**

This next-generation sequencing (NGS) assay is performed to test for the presence of a pathogenic variant in targeted regions of 17 genes. See [Targeted Genes Interrogated by NGENZ Next-Generation Sequencing](#) for details regarding the

targeted gene regions identified by this test. This is a laboratory-developed test.

NGS is performed using a Illumina instrument with paired-end, 151-base pair (bp) reads. The DNA is prepared for NGS using a custom Agilent SureSelect Target Enrichment System. Data is analyzed with the CLC Genomics Server Program. Supplemental or confirmatory Sanger sequencing is performed when necessary.(Unpublished Mayo method)

Genes analyzed: *AK1, ALDOA, G6PD, GCLC, GPI, GSR, GSS, HBB, HBD, HK1, HMOX1, NT5C3A, PFKM, PGK1, PKLR, TPI1,* and *UGT1A1*

PDF Report

No

Specimen Retention Time

DNA: 3 months

Performing Laboratory Location

Rochester

Fees & Codes

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81443

LOINC® Information

Test ID	Test Order Name	Order LOINC Value
NGENZ	RBC Enzyme Sequencing, V	In Process

Result ID	Reporting Name	LOINC®
NGENS	Specimen Type	31208-2
NGEND	Indication for Test	42349-1
40560	Alterations Detected	82939-0

40561	Interpretation	59465-5
40562	Additional Notes	48767-8
40563	Method Summary	85069-3
40564	Disclaimer	62364-5
40566	Panel Gene List	36908-2
40567	Reviewed By	18771-6